Schneeweiss S - Search Results

1

Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.

Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Wang PS, et al. Among authors: schneeweiss s. Ann Epidemiol. 2004 Apr;14(4):296-303. doi: 10.1016/j.annepidem.2003.09.012. Ann Epidemiol. 2004. PMID: 15066610

2

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Schneeweiss S, et al. N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087. N Engl J Med. 2002. PMID: 11893794 Free article.

3

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Schneeweiss S, et al. CMAJ. 2002 Mar 19;166(6):737-45. CMAJ. 2002. PMID: 11944760 Free PMC article.

4

Clozapine use and risk of diabetes mellitus.

Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Wang PS, et al. Among authors: schneeweiss s. J Clin Psychopharmacol. 2002 Jun;22(3):236-43. doi: 10.1097/00004714-200206000-00002. J Clin Psychopharmacol. 2002. PMID: 12006892

5

Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling AK, Avorn J. Schneeweiss S, et al. Eur J Clin Pharmacol. 2002 Jul;58(4):285-91. doi: 10.1007/s00228-002-0467-0. Epub 2002 Jun 12. Eur J Clin Pharmacol. 2002. PMID: 12136375

6

Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance.

Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Schneeweiss S, et al. J Clin Epidemiol. 2002 Aug;55(8):833-41. doi: 10.1016/s0895-4356(02)00437-7. J Clin Epidemiol. 2002. PMID: 12384199

7

Pharmaceutical cost containment with reference-based pricing: time for refinements.

Schneeweiss S, Maclure M, Dormuth C, Avorn J. Schneeweiss S, et al. CMAJ. 2002 Nov 26;167(11):1250-1. CMAJ. 2002. PMID: 12451080 Free PMC article. No abstract available.

8

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.

Avorn J, Benner J, Ford I, Ganz DA, Gaw A, Glynn RJ, Jackson J, Lagaay AM, Schneeweiss S, Walley T, Wang PS; Outcomes Research Working Group and the PROSPER Study Group. Avorn J, et al. Among authors: schneeweiss s. Control Clin Trials. 2002 Dec;23(6):757-73. doi: 10.1016/s0197-2456(02)00228-3. Control Clin Trials. 2002. PMID: 12505250

9

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB. Duetz MS, et al. Among authors: schneeweiss s. Clin Ther. 2003 Jan;25(1):273-84. doi: 10.1016/s0149-2918(03)90037-3. Clin Ther. 2003. PMID: 12637126

10

Improved comorbidity adjustment for predicting mortality in Medicare populations.

Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Schneeweiss S, et al. Health Serv Res. 2003 Aug;38(4):1103-20. doi: 10.1111/1475-6773.00165. Health Serv Res. 2003. PMID: 12968819 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

625 results

Search Page

Filters